Accelerated Appproval US FDA Labeling Guidance Calls Out Surrogate Endpoints Needing Additional Context

Accelerated Appproval: US FDA Labeling Guidance Calls Out Surrogate Endpoints Needing ‘Additional Context’

For Indications and Usage section of some drugs, such as anti-cancer agents, it may be enough merely to state that...

More From BioPortfolio on "Accelerated Appproval: US FDA Labeling Guidance Calls Out Surrogate Endpoints Needing ‘Additional Context’"